Table 1.
Baseline patient characteristics
| No LGE group n = 48 |
Mid-wall LGE group n = 29 |
Multiple LGE lesions group n = 24 |
p-value | |
|---|---|---|---|---|
| Male | 31 (65) | 26 (89) | 18 (75) | 0.06 |
| Age, years | 60.2 ± 12.8 | 63.4 ± 13.4 | 60.1 ± 10.7 | 0.36 |
| NYHA | ||||
| I | 7 (15) | 1 (3) | 6 (25) | 0.06 |
| II | 15 (31) | 5 (17) | 7 (29) | |
| III | 15 (31) | 19 (66) | 8 (33) | |
| IV | 11 (23) | 4 (14) | 3 (13) | |
| NYHA ≥ III | 26 (54) | 23 (79) | 11 (46) | 0.02 |
| BNP, pg/dL | 603 ± 567 | 898 ± 647 | 461 ± 974 | < 0.001 |
| Hypertension | 23 (48) | 16 (55) | 10 (43) | 0.71 |
| Diabetes | 11 (23) | 6 (21) | 4 (17) | 0.95 |
| Creatinine, mg/dL | 0.8 ± 0.2 | 1.0 ± 0.3 | 0.8 ± 0.2 | 0.02 |
| eGFR, ml/min/1.73 m2 | 73.0 ± 25.1 | 60.5 ± 19.1 | 70.0 ± 17.8 | 0.08 |
| Systolic BP, mmHg | 130 ± 25 | 127 ± 23 | 125 ± 21 | 0.76 |
| Diastolic BP, mmHg | 80 ± 18 | 84 ± 20 | 76 ± 15 | 0.39 |
| Atrial fibrillation | 3 (6) | 3 (10) | 3 (13) | 0.60 |
| QRS duration, ms | 111 ± 22 | 109 ± 25 | 120 ± 25 | 0.21 |
| LVEDV, mL | 1780 ± 45 | 196 ± 69 | 168 ± 38 | 0.16 |
| LVESV, mL | 126 ± 44 | 144 ± 64 | 106 ± 29 | 0.02 |
| LVEF, % | 31 ± 10 | 29 ± 10 | 37 ± 8 | 0.007 |
| LGE size, % | 0 | 3.1 ± 3.7 | 22.0 ± 11.7 | < 0.001 |
| Medications | ||||
| Furosemide | 28 (58) | 25 (86) | 13 (57) | 0.02 |
| ACE-i/ARB | 44 (92) | 23 (79) | 18 (78) | 0.18 |
| Spironolactone | 15 (31) | 15 (52) | 8 (35) | 0.20 |
| Beta-blocker | 43 (90) | 28 (97) | 20 (87) | 0.39 |
| Amiodarone | 6 (13) | 8 (28) | 8 (35) | 0.07 |
Values are expressed as mean ± SD or n (%). ACE-i angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BNP brain natriuretic peptide, BP blood pressure, eGFR estimated glomerular filtration rate, LGE late gadolinium enhancement, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, NYHA New York Heart Association classification